Medpace Holdings, Inc. (MEDP) EBITDA
The ebitda for Medpace Holdings, Inc. (MEDP) is $570.50 Million with a year-over-year change of +12.93%. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) measures a company's operating performance by removing non-cash charges and capital structure effects.
MEDP EBITDA Chart
Current EBITDA
$570.50M
$570.50 Million
Year-over-Year Change
+12.93%
vs. $505.17M prior year
Historical Data
13
Years of data available
Annual EBITDA History
| Year | EBITDA | YoY Change | % Change |
|---|---|---|---|
| 2025 | $570.50M | +$65.33M | +12.93% |
| 2024 | $505.17M | +$142.68M | +39.36% |
| 2023 | $362.50M | +$54.39M | +17.65% |
| 2022 | $308.11M | +$85.03M | +38.12% |
| 2021 | $223.08M | +$36.51M | +19.57% |
| 2020 | $186.57M | +$36.12M | +24.01% |
| 2019 | $150.45M | +$10.60M | +7.58% |
| 2018 | $139.85M | +$28.87M | +26.02% |
| 2017 | $110.98M | +$11.52M | +11.59% |
| 2016 | $99.45M | +$10.51M | +11.81% |
| 2015 | $88.95M | $-5.11M | -5.44% |
| 2014 | $94.06M | +$6.40M | +7.30% |
| 2013 | $87.66M | — | — |
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle